AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights

Key Takeaways PFE grows oncology and non-COVID revenues, while also trying to expand its pipeline through acquisitions.ABBV drives strong growth from Skyrizi and Rinvoq while expanding oncology and neuroscience sales.PFE faces COVID softness and upcoming LOEs, while ABBV projects steady growth with no major LOEs.Pfizer (PFE) and AbbVie (ABBV) are both U.S. pharmaceutical giants with a strong leadership position in various therapeutic areas. For Pfizer, oncology sales comprise around 28% of its total revenue ...